Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
Caroline Holm Nørgaard, Sarah Friedrich, Charlotte T. Hansen, et al.
Alzheimer s & Dementia Translational Research & Clinical Interventions (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 109

Showing 51-75 of 109 citing articles:

The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice
Leticia Forny Germano, Jacqueline A. Koehler, Laurie L. Baggio, et al.
Molecular Metabolism (2024) Vol. 89, pp. 102019-102019
Open Access | Times Cited: 5
Emerging Evidence for the Use of Antidiabetic Drugs, Glucagon-like Peptide 1 Receptor Agonists, for the Treatment of Alzheimer’s Disease
Ides M. Colin, Lidia W Szczepanski, A Gérard, et al.
touchREVIEWS in Endocrinology (2023) Vol. 19, Iss. 1, pp. 16-16
Open Access | Times Cited: 11
Unlocking the Potential: Semaglutide’s Impact on Alzheimer’s and Parkinson’s Disease in Animal Models
Andreea-Daniela Meca, Ianis Kevyn Stefan Boboc, Liliana Mititelu-Tarţău, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 6, pp. 5929-5949
Open Access | Times Cited: 4
All GLP-1 Agonists Should, Theoretically, Cure Alzheimer’s Dementia but Dulaglutide Might Be More Effective Than the Others
Jeffrey Fessel
Journal of Clinical Medicine (2024) Vol. 13, Iss. 13, pp. 3729-3729
Open Access | Times Cited: 4
Insulin Resistance, a Risk Factor for Alzheimer’s Disease: Pathological Mechanisms and a New Proposal for a Preventive Therapeutic Approach
Flora Affuso, Filomena Micillo, Sergio Fazio
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1888-1888
Open Access | Times Cited: 4
The etiology and prevention of early‐stage tau pathology in higher cortical circuits: Insights from aging rhesus macaques
Dibyadeep Datta, Amy F.T. Arnsten
Alzheimer s & Dementia (2025)
Open Access
The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review
Victoria J. Old, Melanie J. Davies, Dimitris Papamargaritis, et al.
Journal of Cachexia Sarcopenia and Muscle (2025) Vol. 16, Iss. 1
Open Access
Cognitive dysfunction in diabetes – the ‘forgotten’ diabetes complication: a narrative review
Åke Sjöholm, Louise Bennet, Peter M. Nilsson
Scandinavian Journal of Primary Health Care (2025), pp. 1-7
Open Access
Comparative Effectiveness of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Preventing Alzheimer's Disease, Vascular Dementia, and Other Dementia Types Among Patients with Type 2 Diabetes
Mingyang Sun, Xiaoling Wang, Zhongyuan Lu, et al.
Diabetes & Metabolism (2025), pp. 101623-101623
Closed Access
Real-world datasets for the International Registry for Alzheimer's Disease and Other Dementias (InRAD) and other registries: An international consensus
Robert Perneczky, David Darby, Giovanni B. Frisoni, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100096-100096
Open Access
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists
Naim Alkhouri, Michael Charlton, Meagan Gray, et al.
Expert Opinion on Investigational Drugs (2025)
Closed Access
Sweet Solutions: Unlocking the Diabetes-Dementia Connection for Better Outcomes
Emőke Pósán
Journal of Insurance Medicine (2025) Vol. 52, Iss. 1, pp. 14-20
Closed Access
Glucagon-like peptide-1 receptor agonists and the eye
David Zhang, Avni P. Finn
Current Opinion in Ophthalmology (2025)
Closed Access
Low levels of soluble neuropilin‐1 were associated with depression in adults with newly diagnosed type 2 diabetes
Eva Melin, M. Thunander, P Wanby, et al.
Diabetes Obesity and Metabolism (2025)
Open Access
Cardioprotective Glucose-Lowering Agents and Dementia Risk
Allie Seminer, Alfredi Mulihano, Clare O’Brien, et al.
JAMA Neurology (2025)
Closed Access
Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders
Riccardo De Giorgi, Ana Ghenciulescu, Courtney Yotter, et al.
Journal of Neurology Neurosurgery & Psychiatry (2025), pp. jnnp-335593
Closed Access
The Expanding Role of GLP-1 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health
Mohamad Al Qassab, M.A. Mneimneh, Ahmad Jradi, et al.
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 4, pp. 285-285
Open Access
Neuroinflammatory Biomarkers in Alzheimer’s Disease: From Pathophysiology to Clinical Implications
Fausto Roveta, Lucrezia Bonino, Elisa Maria Piella, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 11941-11941
Open Access | Times Cited: 3
Research progress on the association of insulin resistance with type 2 diabetes mellitus and Alzheimer’s disease
Miao Zheng, Can Wang, Min Hu, et al.
Metabolic Brain Disease (2024) Vol. 40, Iss. 1
Closed Access | Times Cited: 3
The Potential of Genetic Data for Prioritizing Drug Repurposing Efforts
Dipender Gill, Marijana Vujković
Neurology (2022) Vol. 99, Iss. 7, pp. 267-268
Closed Access | Times Cited: 15
DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce α-Synuclein Levels in the 6-OHDA Parkinson’s Disease Rat Model
Lingyu Zhang, Chun Li, Zijuan Zhang, et al.
Parkinson s Disease (2022) Vol. 2022, pp. 1-11
Open Access | Times Cited: 13
Inhibition of CXXC5 function rescues Alzheimer’s disease phenotypes by restoring Wnt/β-catenin signaling pathway
Minguen Yoon, Heejene Kim, Heewon Shin, et al.
Pharmacological Research (2023) Vol. 194, pp. 106836-106836
Open Access | Times Cited: 7
Diabetes and brain disorders, a new role for insulin?
Bastiaan E. de Galan
Neuroscience & Biobehavioral Reviews (2024) Vol. 163, pp. 105775-105775
Open Access | Times Cited: 2
Current perspectives on prevention of vascular cognitive impairment and promotion of vascular brain health
Raj N. Kalaria, Rufus Akinyemi, Stella‐Maria Paddick, et al.
Expert Review of Neurotherapeutics (2023) Vol. 24, Iss. 1, pp. 25-44
Open Access | Times Cited: 6
Comparing major and mild cognitive impairment risks in older type-2 diabetic patients: a Danish register-based study on dipeptidyl peptidase-4 inhibitors vs. glucagon-like peptide-1 analogues
Vera Battini, María Antonietta Barbieri, Carla Carnovale, et al.
Journal of Neurology (2024) Vol. 271, Iss. 6, pp. 3417-3425
Open Access | Times Cited: 2

Scroll to top